Aim
===

To compare the metabolomic profile of adolescents with T1D (≥5 years duration) to controls using gas chromatography--mass spectrometry (GC-MS).

Methods
=======

Design Case control study. Setting Tertiary paediatric hospital clinic. Population 27 (14F/13M) adolescents with T1D (age (median, interquartile range) 15.5, 14.7-16.4 years; duration 7.7; 6.0-11.8 years; HbA1c 9.1, 8.1-10.1%); glucose 13.35 (7.60-17.85) and 27 (14F/13M) control participants (age 15.1, 14.4-16.8 years). BMI was \<95^th^ percentile. Measures Fasting plasma and urine metabolomes were profiled by GC-MS and compared between cohorts. Statistics Univariate comparisons:-Spearman correlations, t-tests/Wilcoxon rank sum tests. Multivariate comparisons:-PCA, OPLS-DA and OPLS.

Results
=======

For GC-MS (plasma and urine), the molecule most influential in separating the two groups was identified as 1,5-anhydroglucitol (1,5-AG) a metabolically inert polyol that is a short-term marker of glycaemic control (7-14 days). It competes with glucose for reabsorption in the kidneys. Otherwise stable levels of 1,5-AG are rapidly depleted as blood glucose levels exceed the renal threshold for glycosuria. 1,5-AG was more influential on group classification than fasting glucose or HbA1c.

Multivariate regression modelling of the plasma data (glucose signals removed) was performed against glucose and HbA1c groups (glucose:4.2-5.4mmol/L, 5.3-9.9mol/L, 11.0-36.7mmol/L; HbA1c:4.7-6.0%, 7.3-9.2%, 9.9-15.4%). Three distinct groups emerged for each variable indicating clear metabolomic differences.

Conclusion
==========

Metabolomic profiling was feasible in this context. GC-MS revealed a "marker" distinguishing the two groups without any bias for or targeting of the analyte. The metabolic profile of the adolescents with diabetes appears to be most influenced by short-term (7-14days) hyperglycaemia. The planned GC-MS fatty acid methyl ester (FAME) analysis and Liquid Chromatography-MS will reduce inherent interference by glucose and provide a more comprehensive coverage of the metabolome.

A 1,5-AG blood assay (GlycoMark) is not yet routinely available in pathology laboratories in Australia. Due to discussions following this study, it may shortly become available. Its particular utility is to assess recent glycaemic control and suggest unrecognised postprandial hyperglycaemia in moderately-controlled (HbA1c 6.5-8%) patients.
